Evidence map›Paper›PMID 26772753›Full record

Observational studyBMC psychiatry2016

Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study).

Elisabeth Giraud-Baro, Daniel Dassa, Florent De Vathaire, Ricardo P Garay, Joelle Obeid

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMC psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2021
    Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elisabeth Giraud-BaroHospital Center of Saint-Egrève, Saint-Egrève, France. egiraudbaro@orange.fr.
Daniel DassaCHU La Timone, Marseilles, France. Daniel.DASSA@ap-hm.fr.
Florent De VathaireINSERM U1018, Institute Gustave Roussy, Villejuif, France. florent.DEVATHAIRE@gustaveroussy.fr.
Ricardo P GarayCraven, Villemoisson-sur-Orge, France. ricardo.garay@orange.fr.
Joelle ObeidJanssen-Cilag France, Issy Les Moulineaux, France. jobeid@its.jnj.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies showed functional improvement in stable patients with schizophrenia treated with risperidone long-acting injection (LAI). We therefore re-investigated functional improvement with risperidone LAI in remitted patients, in comparison with stable patients. The study was conducted in real-life conditions because of the high heterogeneity of the patients' situations.

methodThis was a multi-centre, prospective observational cohort study involving adult schizophrenia-spectrum chronic patients who were previously treated with risperidone LAI for 6 months. Remission was evaluated using the consensus criteria proposed by the Remission in Schizophrenia Working Group (RSWG). The primary endpoint was global functioning (assessed with the Global Assessment of Functioning scale, GAF) after one year of treatment. Social functioning was a secondary outcome.

resultsThe analysis included 1490 patients. Attrition rate was 9.1 % at the end of the study. 27.7 % of patients were in remission after one year of risperidone LAI treatment. The mean GAF rating score (62.5 ± 1.5) was higher than the cut-off previously used to identify patients with satisfactory functioning (60) and significantly higher than the mean GAF score in stable, non-remitted patients (48.3, p < 0.001). Social functioning was also high in remitted patients (21.0 ± 3.6 vs. 17.2 ± 3.7 in non-remitted patients, p < 0.001).

conclusionThe results clearly show that after one year of treatment with risperidone LAI, RSWG-remitted patients have a high level of global functioning, which is significantly higher than in stable, non-remitted patients. Social functioning was also higher in remitted patients as compared with stable, non-remitted patients.

Indexed as

AdolescentAdultAgedAntipsychotic AgentsDelayed-Action PreparationsFemaleHumansMaleMiddle AgedProspective StudiesPsychiatric Status Rating ScalesRemission InductionRisperidoneSchizophreniaSocial BehaviorTreatment OutcomeAntipsychotic AgentsDelayed-Action PreparationsRisperidone

Identifiers

PMID26772753
PMCPMC4714464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.